USO 24112
A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (CLND6) (TORL123-002)
Disease Types: GYN Cancer Research
Eligibility Requirements:
• Histologically or cytologically confirmed diagnosis of advanced
(unresectable) or metastatic high grade serous OC/PP/FPC
• High-grade endometrioid permitted
• Clear cell, mucinous, sarcomatous (including carcinosarcoma),
mixed histology, or low-grade, borderline ovarian tumors or nonepithelial ovarian cancers are excluded
• Pt must have platinum-resistant disease
• Primary plt-refractory excluded
• 1-3 prior systemic lines of therapy, eligible for single-agent as next tx
• Tumor must be CLDN6+
• >30% tumor cell membrane staining of any intensity by IHC
• Measurable disease per RECIST v1.1
• Prior tx with CLDN6-targeting agent or MMAE-containing ADC excluded
For more information on this trial CLICK HERE .
Available at: